Vaccines
Solution Focus

Assays for Vaccines

Supporting a Diverse Range of Vaccine Types

BioAgilytix, working with an array of both emerging and large pharmabio customers, provides robust, compliant bioanalytical assessments for the diverse range vaccine varieties in development today. With leading expertise in complex biologics and a broad suite of advanced platforms, we can apply the optimal, phase-appropriate method to meet your unique vaccine program needs.

Find Answers to How BioAgilytix Supports Assays for Vaccines:

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements with one of our scientists.

Vaccine Development: Support for a Broad Range of Formats

Vaccine development is one of the most diverse and fastest growing areas in pharmaceuticals and biotechnology. The serious impacts of infectious diseases like Ebola, malaria, HIV, and COVID-19 on world health have continued to make vaccines a focus of substantial social consideration, and new generations are being explored to find cures for diseases with no effective treatments yet available.

BioAgilytix’s deep experience in cell-based assays, immunology, and potency assay development for biologics enables us to effectively collaborate with sponsors on complex bioanalytical assessments for diverse vaccine varieties. Generation 1 vaccines, which are infectious agent-based, still hold a significant position in disease prevention. Our expertise in developing a range of immune-based methods on a broad set of platforms allows us to efficiently develop these assays under GMP regulatory expectations.

The development of Generation 2 and 3 vaccines, which can include recombinant proteins and virus-like particles (VLPs), nucleic acid- or vector-based vaccines, and emerging virus neutralization approaches such as monoclonal antibodies directed at the target virus, have grown significantly owing to their relative control, reduced risk, and targeted effectiveness. These products are often initially developed using animal models and determination of immune response. Industry focus to address the ‘3Rs‘ – replace, reduce, refine – to minimize the use of animal testing has driven their transition to in vitro potency assays which are often met using immune-based methods. In some instances, this method is complemented with an in vivo assay or a cell-based assay. Cell-based assays for these vaccines are typically required to demonstrate mode of action (i.e. particle or protein interaction with a target cell).

 

virus neutralization methods

On-Demand Webinar

Accelerating Testing of Therapeutics to Neutralize Viral Infections

We summarize key insights from our recent study to translate diagnostic virus neutralization method to a quantitative cell-based assay for the determination of relative potency of an anti-influenza antibody.

Access Recording

 

Optimal Platforms for Vaccine Assays: Plate-Based Methods

The science behind vaccines has advanced substantially in recent years – as have regulatory expectations. Potency assays have evolved from simple titers to relative potency determinations to demonstrate appropriate control of the product. The 3Rs initiative is also driving more vaccine testing to move from in vivo animal models to in vitro using epitope-targeted ELISAs or cell-based assays with immune-pertinent systems.

BioAgilytix’s expertise in developing a range of ELISA and cell-based assays for biologics and gene & cell therapies on a broad set of platforms, paired with our specialization in immunology and with ADA and NAb assays, ensures your vaccine products are well-positioned to successfully advance down the development and approval pathways.

flow cytometry for vaccines

Flow Cytometry

elisa platform for vaccines

ELISA

platform for pkpd durham

ELISPOT

msd assays for vaccines

MSD-ECL

platform for pkpd durham

qPCR

A Full Range of Phase-Appropriate Methods for Vaccine Assessments

Our experience is deep across the range of assays below performed under GLP, GCP, and GMP regulations:

Flow Cytometry

  • T Cell, B Cell & NK Panels
  • T and B Cell Activation Markers & Tetramer Staining
  • Specific Cell Population Isolations
  • Vaccine-Induced T Cell Enumeration

ELISA

  • Antibody Titers
  • Anti-drug Antibodies (ADA)
  • Seroconversion
  • Host Cell Proteins

Cell-Based Assays

  • Neutralizing Antibodies (NAb)
  • Potency Assays

ELISPOT

  • Enumeration of Antigen-Specific Cellular Response
  • Immune Response Monitoring

MSD-ECL

  • Validated Cytokine/Chemokine Panels
  • Vaccine Antigen Detection

qPCR & ddPCR

  • Viral Load
  • Genotyping
  • Gene Expression
  • Immune Response Monitoring
  • Host Cell DNA

Through these comprehensive assessments we are able to help ensure your vaccine products are well-positioned to successfully advance down the development and approval pathways.

platforms for vaccine assays

bioanalysis for vaccines

assays for vaccines

Download Our Vaccine Brochure

Explore the assays we use to support assessments of pathogen-derived vaccines, recombinant proteins and LVPs, nucleic acid- or vector-based vaccines, and emerging virus neutralization approaches.

Download Brochure

Partner with BioAgilytix to Efficiently Advance Your Vaccine Program

BioAgilytix’s GMP staff has more than 100 years of collective experience in developing immune-based methods and cell-based assays to measure potency, which we leverage in testing for a myriad of vaccine types. We validate assays to ICH standards and apply phase-appropriate criteria to support your vaccine program lifecycle from early phase development through pre-commercial/Phase III efforts. We’ll work closely to define your specific assay requirements and facilitate selection of the best platform for everything from short-term feasibility studies to long-term robust product release testing.

vaccine development partner

Speak to a Scientist







With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

Find premier bioanalytical services for all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Resource Center

Find an array of scientific resources developed by our team of leading large molecule specialists.

Explore Now